| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 10-Q |
| 12 Nov 2026 | SCHEDULE 13D/A |
| 12 Nov 2026 |
Form 4: Dafna Capital Management Llc, 10% owner and 1 other
Acquired 0 Convertible Promissory Notes (Open Market Purchase) |
| 12 Nov 2026 |
Form 4: Fischel Nathan, Director
Acquired 0 Convertible Promissory Notes (Open Market Purchase) |
| 10 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
St. Louis, November 10, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the th... |
| 19 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | EFFECT |
| 13 Aug 2026 | EFFECT |
| 13 Aug 2026 | 424B3 |
| 13 Aug 2026 | 424B3 |
| 12 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially |
| 16 Jul 2026 |
8-K: Other Events
We may be unable to successfully integrate Robocath into our business and may fail to realize any or all of the anticipated benefits of the acquisition, or those benefits may take longer to realize than expected. |
| 15 Jul 2026 | S-3 |
| 15 Jul 2026 | S-3 |
| 09 Jul 2026 |
8-K: Unregistered Sales of Equity Securities; Regulation FD Disclosure +1 more
St. Louis, USA & Rouen, France, July 9, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previo... |
| 01 Jul 2026 |
Form 4: Shamir Nachum, Director
Received 43,103 shares as a grant or award |
| 01 Jul 2026 |
Form 4: Benfer David, Director
Received 43,103 shares as a grant or award |
| 01 Jul 2026 |
Form 4: Levin Ross B, Director
Received 43,103 shares as a grant or award |
| 01 Jul 2026 |
Form 4: Curet Myriam, Director
Received 43,103 shares as a grant or award |
Loading...